Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
353 Leser
Artikel bewerten:
(2)

Karo Healthcare appoints Konstanze Gallinatus as Chief Transformation Officer

Karo Healthcare ("Karo") has appointed Konstanze Gallinatus as Chief Transformation Officer and member of the Corporate Management Team.

STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- The appointment of Konstanze reflects Karo's significant growth ambitions in the years ahead and the steps Karo is taking to develop, strengthen and streamline the company. Karo's vision is to become a leading European consumer healthcare company with revenues of more than EUR 1 billion and industry-leading profitability by 2030, fueled by continued M&A and by unlocking long-term value from every acquisition. Her extensive experience in transformation, pricing, and demand management brings valuable expertise to Karo's leadership team.

"We are excited to welcome Konstanze to Karo. With her strong leadership capabilities and track record in transformation, execution, and value creation in a private equity context, she will be instrumental in Karo's next growth journey with KKR and the realization of our value creation plan. Subject to regulatory approvals, Konstanze will also take a key role in supporting the future integration of the Perrigo Skin Health business. I very much look forward to working with her," says Christoffer Lorenzen, CEO.

Konstanze joins Karo in January 2026 from Douglas Group AG, the leading European omnichannel retailer for premium beauty, where she spent seven years as a member of the Executive Committee. In her role as Executive Vice President for Program Management Office and Chief Pricing & Demand Officer, she was responsible for strategy and transformation, pricing, and demand forecasting and replenishment, leading the company's transformation in close collaboration with its private equity owner, CVC. Among her achievements were the development and implementation of Douglas' value creation plan, resulting in more than €100m in EBITDA improvement, as well as the establishment of centralised pricing and demand forecasting teams.

Prior to Douglas, Konstanze started her career at OC&C Strategy Consultants and held C-level positions at various start-up companies, including CEO of Aklebia eCare Solutions and CFO of Springlane.

"I am very excited to join Karo at this important point in its development. The company has built a strong foundation, achieved impressive growth, and established a clear position in consumer healthcare. I look forward to contributing my experience and working closely with Christoffer, the management team, all colleagues at Karo and its new owner KKR to further strengthen the company's transformation and growth journey," says Konstanze Gallinatus.

For further information, please contact:
Christoffer Lorenzen, CEO, +46 735 017 620, christoffer.lorenzen@karo.com
Lisa Westerdahl, Chief People & Sustainability Officer, +46 733 297 004, lisa.westerdahl@karo.com

The information was submitted for publication by the contact persons set out above, at 9:00 CET on 30 September 2025.

About Karo Healthcare

Karo Healthcare is a leading European consumer healthcare company with the purpose of delivering 'Smart choices for everyday healthcare', empowering people to live life to the fullest. Our products are available in more than 90 countries and include trusted original brands such as Lamisil®, E45®, Pevaryl®, Proct®, AlphaFoods, Nutravita, Flux®, Locobase®, Multi-Gyn® and Paracet®. Headquartered in Stockholm, Karo employs about 470 people who work out of Karo's 13 international hubs. For more info, visit karohealthcare.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/karo-healthcare/r/karo-healthcare-appoints-konstanze-gallinatus-as-chief-transformation-officer,c4242938

The following files are available for download:

https://mb.cision.com/Main/72/4242938/3695687.pdf

Press release (PDF)

Cision View original content:https://www.prnewswire.co.uk/news-releases/karo-healthcare-appoints-konstanze-gallinatus-as-chief-transformation-officer-302570512.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.